Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
Pippa Newell(Hood Technology (United States)), Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Myron Schwartz(Icahn School of Medicine at Mount Sinai), Maria Isabel Fiel(Icahn School of Medicine at Mount Sinai), Radoslav Savić(Tisch Hospital), Laia Cabellos(Icahn School of Medicine at Mount Sinai), Clara Alsinet(Hospital Clínic de Barcelona), Beatriz Mínguez, Judit Peix, Victoria Tovar(Hospital Clínic de Barcelona), Augusto Villanueva(NYU Langone Health), Kemal Denız(Erciyes University), Derek Y. Chiang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Scott L. Friedman(Icahn School of Medicine at Mount Sinai), Jordi Bruix(Hospital Clínic de Barcelona), Swan N. Thung(Icahn School of Medicine at Mount Sinai), Kiat Hon Lim(Singapore General Hospital), Sara Toffanin(UiT The Arctic University of Norway), Pedro Melgar‐Lesmes(Icahn School of Medicine at Mount Sinai), Yujin Hoshida(Broad Institute), Sasan Roayaie(White Plains Hospital), Steven Yea(Array BioPharma (United States))
Cited by 222
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k